Suppression of MMQ cells by fulvestrant: Possible mechanism of action and potential application for bromocriptine-resistant prolactinomas

Journal of Clinical Neuroscience

Volumn 20, Issue 5, 2013, Pages 721-725

  Bai, Jiwei ^a   Gui, Songbai ^a   Zhang, Yazhuo ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Catenin; Estrogen receptor ; Fulvestrant; Prolactinoma; Wnt inhibitory factor 1; Wnt pathway

Indexed keywords

BETA CATENIN; BROMOCRIPTINE; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; MESSENGER RNA; PROLACTIN; REGULATOR PROTEIN; UNCLASSIFIED DRUG; WNT INHIBITORY FACTOR 1;

ADULT; ANIMAL CELL; ARTICLE; BETA CATENIN GENE; BROMOCRIPTINE RESISTANT PROLACTINOMA; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ESTROGEN RECEPTOR ALPHA GENE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYPOPHYSIS CELL; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROLACTINOMA; RAT; SEX DIFFERENCE; TUMOR VOLUME; WNT INHIBITORY FACTOR 1 GENE; WNT SIGNALING PATHWAY;

ADULT; ANIMALS; BETA CATENIN; BROMOCRIPTINE; CELL LINE; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; FEMALE; HORMONE ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTINOMA; RATS; YOUNG ADULT;

EID: 84876687031     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2012.07.008     Document Type: Article

References (27)

1. A. Klibanski Dopamine agonist therapy in prolactinomas: when can treatment be discontinued? J Clin Endocrinol Metab 94 2009 2247 2249
2. M.C. Oh, and M.K. Aghi Dopamine agonist-resistant prolactinomas J Neurosurg 114 2011 1369 1379
3. J.M. Lopez, and E. Oestreicher Reversal of hypogonadotropic hypogonadism with tamoxifen in a patient with hyperprolactinemia resistant to dopamine agonists Fertil Steril 84 2005 756
4. S. Lamberts, T. Verleun, and R. Oosterom Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas Neuroendocrinology 34 1982 339 342
5. Z. Jiang, S. Gui, and Y. Zhang Analysis of differential gene expression by fiber-optic BeadArray and pathway in prolactinomas Endocrine 38 2010 360 368
6. T. Miyakoshi, M. Takei, and H. Kajiya Expression of Wnt4 in human pituitary adenomas regulates activation of the beta-catenin-independent pathway Endocr Pathol 19 2008 261 273
7. M.S. Elston, A.J. Gill, and J.V. Conaglen Wnt pathway inhibitors are strongly down-regulated in pituitary tumors Endocrinology 149 2008 1235 1242
8. A. Giles, F. Madec, and S. Friedrichsen Wnt signalling in estrogen-induced lactotroph proliferation J Cell Sci 124 2011 540 547
9. M. Jonsson, J. Dejmek, and P.O. Bendahl Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas Cancer Res 62 2002 409 416
10. W.J. Nelson, and R. Nusse Convergence of Wnt,{beta}-catenin, and cadherin pathways Science 303 2004 1483
11. P. Polakis Wnt signaling and cancer Genes Dev 14 2000 1837 1851
12. A.P. Kouzmenko, K. Takeyama, and S. Ito Wnt/beta-catenin and estrogen signaling converge in vivo J Biol Chem 279 2004 40255 40258
13. T. Miyakoshi, H. Kajiya, and K. Miyajima The expression of Wnt4 is regulated by estrogen via an estrogen receptor alpha-dependent pathway in rat pituitary growth hormone-producing cells Acta Histochem Cytochem 42 2009 205 213
14. C. Li, Z. Sun, and S. Gui Effects of fulvestrant, an estrogen receptor antagonist, on MMQ cells and its mechanism Neuro Endocrinol Lett 30 2009 268 274
15. H. Lv, C. Li, and S. Gui Effects of estrogen receptor antagonist on biological behavior and expression of growth factors in the prolactinoma MMQ cell line J Neurooncol 102 2011 237 245
16. L. Leng, and Y. Zhang Effects of an estrogen receptor antagonist on proliferation, prolactin secretion and growth factor expression in the MMQ pituitary prolactinoma cell line J Clin Neurosci 18 2011 1694 1698
17. DeLellis RA, Lloyd RV, Heitz PU, et al. Pathology and genetics of tumours of endocrine organs. WHO classification of tumours. The International Agency for Research on Cancer, Lyon, France 2004.
18. P. Lundin, and F. Pedersen Volume of pituitary macroadenomas: assessment by MRI J Comput Assist Tomogr 16 1992 519
19. K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2-[Delta][Delta] CT method Methods 25 2001 402 408
20. M. Gueorguiev, and A.B. Grossman Pituitary gland and beta-catenin signaling: from ontogeny to oncogenesis Pituitary 12 2009 245 255
21. M.S. Elston, and R.J. Clifton-Bligh Identification of Wnt family inhibitors: a pituitary tumor directed whole genome approach Mol Cell Endocrinol 326 2010 48 54
22. C.O. Evans, C.S. Moreno, and X. Zhan Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses Pituitary 11 2008 231 245
23. R.D. Calle-Rodrigue, C. Giannini, and B.W. Scheithauer Prolactinomas in male and female patients: a comparative clinicopathologic study Mayo Clin Proc 73 1998 1046 1052
24. E. Delgrange, J. Trouillas, and D. Maiter Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study J Clin Endocrinol Metab 82 1997 2102 2107
25. S. Zarate, and A. Seilicovich Estrogen receptors and signaling pathways in lactotropes and somatotropes Neuroendocrinology 92 2010 215 223
26. M.E. Lieberman, R.A. Maurer, and J. Gorski Estrogen control of prolactin synthesis in vitro Proc Natl Acad Sci USA 75 1978 5946 5949
27. K.M. Scully, A.S. Gleiberman, and J. Lindzey Role of estrogen receptor-alpha in the anterior pituitary gland Mol Endocrinol 11 1997 674 681